Table 3 Comparison of the clinicopathological features and Patient prognosis in the CAPZA1 underexpression and overexpression
From: CAPZA1 modulates EMT by regulating actin cytoskeleton remodelling in hepatocellular carcinoma
Levels of CAPZA1 expression | P-value | ||
|---|---|---|---|
Underexpression 0,1+ | Overexpression 2+,3+,4+ | ||
Mean tumor size(cm) | 8.0 ± 2.4 | 6.8 ± 3.6 | 0.032 |
TNM stage | <0.001 | ||
StageI | 2(3.4%) | 24(34.3%) | |
StageII | 0(0%) | 13(18.6%) | |
StageIII-IV | 57(96.6%) | 33(47.2%) | |
HCC differentiation | <0.001 | ||
WD | 0(0%) | 10(14.3%) | |
MD | 36(61.0%) | 58(82.9%) | |
PD | 23(39.0%) | 2(2.9%) | |
Lymph node metastasis | 9/59(15.3%) | 3/70(4.3%) | 0.033 |
Vascular invasion | 33/59(55.9%) | 20/70(28.6%) | 0.002 |
Extrahepatic metastasis | 24/59(40.7%) | 13/70(18.6%) | 0.006 |
Postoperative recurrence | 56/59(94.9%) | 35/70(50%) | <0.001 |
Cancer related death | 54/59(91.5%) | 27/70(38.6%) | <0.001 |